Alpha Therapeutic Corp., of Los Angeles, promoted Edward Colton to chief operating officer.
Anadys Pharmaceuticals Inc., of San Diego, appointed Cheryl Lawton as senior vice president of Boston operations and general counsel, and Alexander Chucholowski as senior director of chemistry.
AnorMED Inc., of Vancouver, British Columbia, named Gary Calandra vice president of clinical development.
Aviron, of Mountain View, Calif., elected R. Gordon Douglas to its board of directors. Douglas is currently a consultant to the Vaccine Research Center at the National Institutes of Health.
Axys Pharmaceuticals Inc., of South San Francisco, named David Riggs senior vice president and chief financial officer.
Cell Genesys Inc., of Foster City, Calif., said Robert Tidwell joined the company as vice president, corporate development.
Cholestech Corp., of Hayward, Calif., said John Landon is now chairman of the board of directors. Landon has been a director at Cholestech since 1997. The company also named Molly Coye to the board.
Cohesion Technologies Inc., of Palo Alto, Calif., named Thomas Prescott to the board of directors.
Corixa Corp., of Seattle, named James Young to its board of directors. Young is chief executive officer of Sunesis Pharmaceuticals Inc.
Deltagen Inc., of Menlo Park, appointed Richard Hawkins as chief financial officer.
GeneTrace Systems Inc., of Alameda, Calif., appointed Leslie Browne as chief operating officer.
Genomics One Corp., of Laval, Quebec, appointed Michel Cousineau director of business development and marketing.
Huntsman Cancer Institute, of Salt Lake City, named William Carroll deputy director.
MGI Pharma Inc., of Minneapolis, named Michael Cullen vice president, clinical affairs, and chief medical officer.
Mycota Biosciences Inc., of Montreal, named Jeffrey Becker to its scientific advisory board.
Nanogen Inc., of San Diego, appointed Kieran Gallahue president.